The Company is a biotechnology company specializing in the development of high-affinity sheep monoclonal antibodies (SMAs) for use in immunodiagnostics focusing on the areas of clinical diagnostics and drugs of abuse testing. The Company uses its technology in the fields of clinical diagnostics. Its develops products for Thyroid, Fertility, Oncology, Vitamin D, Drugs of Abuse and other diseases. Its product, Vitamin D SMA is a steroid hormone involved in the intestinal absorption of calcium and the regulation of calcium homeostasis but it has also evolved into a hormone that has a diversity of biologic effects.
Company Growth (employees)
Farnham, GB
Size (employees)
14 (est)+8%
Bioventix is headquartered in Farnham, GB

Bioventix Office Locations

Bioventix has office in Farnham
Farnham, GB

Bioventix Metrics

Bioventix Summary

Market capitalization

£90.4 m

Closing share price

Bioventix's current market capitalization is £90.4 m.

Bioventix Financials

Bioventix's revenue is £5.5 m in FY, 2016 which is a 27.3% increase from the previous period.
FY, 2014FY, 2015FY, 2016


£3.5 m£4.3 m£5.5 m

Revenue growth, %


Cost of sales

£302.9 k£320.5 k£494.9 k

Gross profit

£3.2 m£4 m£5 m

Gross profit Margin, %


Operating expense total

£1 m£915.2 k£816.9 k

Bioventix Market Value History

We estimate that Bioventix's current employees are approximately 100% male

Bioventix Company Life

You may also be interested in